CoChat

Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes

Kútna, Viera, O'Leary, Valerie B., Newman, Ehren, Hoschl, Cyril, Ovsepian, Saak V. · 2021 · Neurotherapeutics
Cited by 11

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13311-020-01000-7

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 109

  1. Crino, P.B., mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med, 2015. 5(4):a022442. https://doi.org/10.1101/cshperspect.a022442. · DOI · Paper page
  2. Saxton, 2017, mTOR Signaling in Growth, Metabolism, and Disease, Cell, 169, 361, 10.1016/j.cell.2017.03.035 · DOI · Paper page
  3. Dentel, 2019, Therapeutic Targeting of mTORC2 in mTORopathies, Neuron, 104, 1032, 10.1016/j.neuron.2019.11.026 · DOI
  4. Richardson, 1991, Pathology of tuberous sclerosis. Neuropathologic aspects, Ann N Y Acad Sci, 615, 128, 10.1111/j.1749-6632.1991.tb37755.x · DOI
  5. Vinters, 1999, Cortical dysplasia, genetic abnormalities and neurocutaneous syndromes, Dev Neurosci, 21, 248, 10.1159/000017404 · DOI
  6. Eker, 1954, Familial renal adenomas in Wistar rats; a preliminary report, Acta Pathol Microbiol Scand, 34, 554, 10.1111/j.1699-0463.1954.tb00301.x · DOI
  7. Eker, 1981, Hereditary renal adenomas and adenocarcinomas in rats, Diagn Histopathol, 4, 99
  8. Yeung, 1997, Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis, Am J Pathol, 151, 1477
  9. Kutna, 2020, Tuberous Sclerosis (tsc2+/-) Model Eker Rats Reveals Extensive Neuronal Loss with Microglial Invasion and Vascular Remodeling Related to Brain Neoplasia, Neurotherapeutics, 17, 329, 10.1007/s13311-019-00812-6 · DOI · Paper page
  10. Waltereit, 2006, Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis, J Neurochem, 96, 407, 10.1111/j.1471-4159.2005.03538.x · DOI · Paper page
  11. Rennebeck, 1998, Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development, Proc Natl Acad Sci U S A, 95, 15629, 10.1073/pnas.95.26.15629 · DOI · Paper page
  12. Knudson, 1971, Mutation and cancer: statistical study of retinoblastoma, Proc Natl Acad Sci U S A, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
  13. Tomlinson, 2001, Two hits revisited again, J Med Genet, 38, 81, 10.1136/jmg.38.2.81 · DOI
  14. Afshar Saber, 2020, Recent advances in human stem cell-based modeling of Tuberous Sclerosis Complex, Mol Autism, 11, 16, 10.1186/s13229-020-0320-2 · DOI · Paper page
  15. Blair, 2020, New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids, Dev Dyn, 249, 46, 10.1002/dvdy.60 · DOI
  16. Robertson, F.L., et al., Experimental models and tools to tackle glioblastoma. Dis Model Mech, 2019. 12(9):dmm040386. https://doi.org/10.1242/dmm.040386. · DOI
  17. Parsa, 2000, Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy, Neurosurgery, 47, 993, 10.1097/00006123-200010000-00050 · DOI
  18. Workman, 2010, Guidelines for the welfare and use of animals in cancer research, Br J Cancer, 102, 1555, 10.1038/sj.bjc.6605642 · DOI · Paper page
  19. Simons, B.W. and C. Brayton, Challenges and Limitations of Mouse Xenograft Models of Cancer. Patient Derived Tumor Xenograft Models, ed. R. Uthamanthil and P. Tinkey. 2016, Johns Hopkins University School of Medicine, Baltimore, MD, United States: Academic Press. · DOI
  20. Kim, 2016, Failure of a patient-derived xenograft for brain tumor model prepared by implantation of tissue fragments, Cancer Cell Int, 16, 43, 10.1186/s12935-016-0319-0 · DOI
  21. Fryer, 1987, Evidence that the gene for tuberous sclerosis is on chromosome 9, Lancet, 1, 659, 10.1016/S0140-6736(87)90416-8 · DOI · Paper page
  22. Kandt, 1992, Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease, Nat Genet, 2, 37, 10.1038/ng0992-37 · DOI · Paper page
  23. Henske, 2016, Tuberous sclerosis complex, Nat Rev Dis Primers, 2, 16035, 10.1038/nrdp.2016.35 · DOI · Paper page
  24. Lam, 2018, Renal disease in tuberous sclerosis complex: pathogenesis and therapy, Nat Rev Nephrol, 14, 704, 10.1038/s41581-018-0059-6 · DOI
  25. Bongaarts, 2017, Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations, Oncotarget, 8, 95516, 10.18632/oncotarget.20764 · DOI
  26. Rosset, 2017, TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review, Genet Mol Biol, 40, 69, 10.1590/1678-4685-gmb-2015-0321 · DOI
  27. Lamb, 2000, The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho, Nat Cell Biol, 2, 281, 10.1038/35010550 · DOI · Paper page
  28. Haddad, 2002, The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton, J Biol Chem, 277, 44180, 10.1074/jbc.M207211200 · DOI · Paper page
  29. Schopel, 2017, The small GTPases Ras and Rheb studied by multidimensional NMR spectroscopy: structure and function, Biol Chem, 398, 577, 10.1515/hsz-2016-0276 · DOI
  30. Kleijer, 2014, Neurobiology of autism gene products: towards pathogenesis and drug targets, Psychopharmacology, 231, 1037, 10.1007/s00213-013-3403-3 · DOI · Paper page
  31. Kobayashi, 1997, Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog, Mamm Genome, 8, 554, 10.1007/s003359900502 · DOI
  32. Maheshwar, 1997, The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis, Hum Mol Genet, 6, 1991, 10.1093/hmg/6.11.1991 · DOI · Paper page
  33. Nussinov, 2020, The Mystery of Rap1 Suppression of Oncogenic Ras, Trends Cancer, 6, 369, 10.1016/j.trecan.2020.02.002 · DOI
  34. Jaskiewicz, A., B. Pajak, and A. Orzechowski, The Many Faces of Rap1 GTPase. Int J Mol Sci, 2018. 19(10):2848. https://doi.org/10.3390/ijms19102848. · DOI
  35. Rubinfeld, 1991, Molecular cloning of a GTPase activating protein specific for the Krev-1 protein p21rap1, Cell, 65, 1033, 10.1016/0092-8674(91)90555-D · DOI · Paper page
  36. Yeung, 2004, Lessons from the Eker rat model: from cage to bedside, Curr Mol Med, 4, 799, 10.2174/1566524043359791 · DOI
  37. Soucek, 1997, Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase, J Biol Chem, 272, 29301, 10.1074/jbc.272.46.29301 · DOI · Paper page
  38. Jin, 2017, Importance of tuberin in carcinogenesis, Oncol Lett, 14, 2598, 10.3892/ol.2017.6490 · DOI
  39. Rosner, 2007, Cytoplasmic/nuclear localization of tuberin in different cell lines, Amino Acids, 33, 575, 10.1007/s00726-007-0541-0 · DOI
  40. Wienecke, 1996, Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus, Oncogene, 13, 913
  41. Demetriades, 2014, Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2, Cell, 156, 786, 10.1016/j.cell.2014.01.024 · DOI · Paper page
  42. Johnson, 2001, Hamartin and tuberin expression in human tissues, Mod Pathol, 14, 202, 10.1038/modpathol.3880286 · DOI
  43. Li, 2018, Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complex, Sci Rep, 8, 13373, 10.1038/s41598-018-31075-4 · DOI
  44. Dan, 2016, Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin, J Biol Chem, 291, 22848, 10.1074/jbc.A116.205838 · DOI
  45. Inoki, 2002, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling, Nat Cell Biol, 4, 648, 10.1038/ncb839 · DOI · Paper page
  46. Ma, 2007, Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer, Cancer Res, 67, 7106, 10.1158/0008-5472.CAN-06-4798 · DOI · Paper page
  47. Nie, 2010, Tsc2-Rheb signaling regulates EphA-mediated axon guidance, Nat Neurosci, 13, 163, 10.1038/nn.2477 · DOI · Paper page
  48. Han, 2008, Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling, Cell Signal, 20, 1084, 10.1016/j.cellsig.2008.01.020 · DOI
  49. Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2 · DOI · Paper page
  50. Lee, 2007, IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway, Cell, 130, 440, 10.1016/j.cell.2007.05.058 · DOI · Paper page
  51. Goncharova, 2002, Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM), J Biol Chem, 277, 30958, 10.1074/jbc.M202678200 · DOI · Paper page
  52. Cheadle, 2000, Molecular genetic advances in tuberous sclerosis, Hum Genet, 107, 97, 10.1007/s004390000348 · DOI · Paper page
  53. Napolioni, 2008, Genetics and molecular biology of tuberous sclerosis complex, Curr Genomics, 9, 475, 10.2174/138920208786241243 · DOI
  54. Osborne, 1991, Epidemiology of tuberous sclerosis, Ann N Y Acad Sci, 615, 125, 10.1111/j.1749-6632.1991.tb37754.x · DOI · Paper page
  55. Samueli, 2015, Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management, Wien Klin Wochenschr, 127, 619, 10.1007/s00508-015-0758-y · DOI
  56. Prather, 2004, Behavioral and cognitive aspects of tuberous sclerosis complex, J Child Neurol, 19, 666, 10.1177/08830738040190090601 · DOI · Paper page
  57. de Vries, 2018, A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND), Am J Med Genet C: Semin Med Genet, 178, 309, 10.1002/ajmg.c.31637 · DOI · Paper page
  58. Gipson, 2013, Potential for treatment of severe autism in tuberous sclerosis complex, World J Clin Pediatr, 2, 16, 10.5409/wjcp.v2.i3.16 · DOI
  59. Hunt, 1987, Psychiatric disorder among children with tuberous sclerosis, Dev Med Child Neurol, 29, 190, 10.1111/j.1469-8749.1987.tb02135.x · DOI · Paper page
  60. Holmes, 2007, Study, Tuberous sclerosis complex and epilepsy: recent developments and future challenges, Epilepsia, 48, 617, 10.1111/j.1528-1167.2007.01035.x · DOI · Paper page
  61. Nabbout, 2019, Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study, Epilepsia Open, 4, 73, 10.1002/epi4.12286 · DOI · Paper page
  62. Braffman, 1992, MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review, Radiology, 183, 227, 10.1148/radiology.183.1.1549677 · DOI · Paper page
  63. Ridler, 2004, Standardized whole brain mapping of tubers and subependymal nodules in tuberous sclerosis complex, J Child Neurol, 19, 658, 10.1177/08830738040190090501 · DOI · Paper page
  64. Peters, 2013, Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions, Future Neurol, 8, 583, 10.2217/fnl.13.37 · DOI
  65. Yamanouchi, 1997, Giant cells in cortical tubers in tuberous sclerosis showing synaptophysin-immunoreactive halos, Brain and Development, 19, 21, 10.1016/S0387-7604(96)00079-4 · DOI
  66. Grajkowska, 2010, Brain lesions in tuberous sclerosis complex. Review, Folia Neuropathol, 48, 139
  67. Fohlen, 2018, Refractory epilepsy in preschool children with tuberous sclerosis complex: Early surgical treatment and outcome, Seizure, 60, 71, 10.1016/j.seizure.2018.06.005 · DOI
  68. Kalantari, 2008, Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging, AJR Am J Roentgenol, 190, W304, 10.2214/AJR.07.2928 · DOI
  69. Yamanouchi, 1997, Evidence of abnormal differentiation in giant cells of tuberous sclerosis, Pediatr Neurol, 17, 49, 10.1016/S0887-8994(97)00036-2 · DOI
  70. Henske, 1997, Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors, Am J Pathol, 151, 1639
  71. DiMario, 2004, Brain abnormalities in tuberous sclerosis complex, J Child Neurol, 19, 650, 10.1177/08830738040190090401 · DOI · Paper page
  72. Goh, 2004, Subependymal giant cell tumors in tuberous sclerosis complex, Neurology, 63, 1457, 10.1212/01.WNL.0000142039.14522.1A · DOI · Paper page
  73. Adriaensen, 2009, Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature, Eur J Neurol, 16, 691, 10.1111/j.1468-1331.2009.02567.x · DOI · Paper page
  74. Cuccia, 2003, Subependymal giant cell astrocytoma in children with tuberous sclerosis, Childs Nerv Syst, 19, 232, 10.1007/s00381-002-0700-2 · doi:10.1007/s00381-002-0700-2
  75. Buccoliero, 2009, Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study, Neuropathology, 29, 25, 10.1111/j.1440-1789.2008.00934.x · DOI
  76. Hirose, 1995, Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study, Acta Neuropathol, 90, 387, 10.1007/BF00315012 · DOI
  77. Di Rocco, 1995, On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis, Pediatr Neurosurg, 23, 115, 10.1159/000120947 · doi:10.1159/000120947
  78. Kim, 2017, Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report, Brain Tumor Res Treat, 5, 37, 10.14791/btrt.2017.5.1.37 · DOI
  79. Ess, 2005, Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex, Neurology, 64, 1446, 10.1212/01.WNL.0000158653.81008.49 · DOI · Paper page
  80. Ess, 2004, Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology, Glia, 46, 28, 10.1002/glia.10324 · DOI
  81. Feng, 1994, Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS, Neuron, 12, 895, 10.1016/0896-6273(94)90341-7 · DOI · Paper page
  82. Jozwiak, 2004, Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis, J Child Neurol, 19, 102, 10.1177/08830738040190020401 · DOI
  83. Mizuguchi, 2000, Novel cerebral lesions in the Eker rat model of tuberous sclerosis: cortical tuber and anaplastic ganglioglioma, J Neuropathol Exp Neurol, 59, 188, 10.1093/jnen/59.3.188 · DOI
  84. Takahashi, 2004, Abnormal cortical cells and astrocytomas in the Eker rat model of tuberous sclerosis complex, Epilepsia, 45, 1525, 10.1111/j.0013-9580.2004.23004.x · DOI · Paper page
  85. Wenzel, 2004, Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis, Acta Neuropathol, 108, 97, 10.1007/s00401-004-0865-8 · DOI
  86. Wippold, 2006, A. Perry, and J. Lennerz, Neuropathology for the neuroradiologist: Rosenthal fibers, AJNR Am J Neuroradiol, 27, 958
  87. Curatolo, 1991, Neuropsychiatric aspects of tuberous sclerosis, Ann N Y Acad Sci, 615, 8, 10.1111/j.1749-6632.1991.tb37743.x · DOI · Paper page
  88. Almobarak, 2018, Tuberous Sclerosis Complex: Clinical Spectrum and Epilepsy: A Retrospective Chart Review Study, Transl Neurosci, 9, 154, 10.1515/tnsci-2018-0023 · DOI
  89. Tschuluun, 2007, Irradiation exacerbates cortical cytopathology in the Eker rat model of tuberous sclerosis complex, but does not induce hyperexcitability, Epilepsy Res, 73, 53, 10.1016/j.eplepsyres.2006.08.003 · DOI
  90. Cooper, 2012, The role of glutamine synthetase and glutamate dehydrogenase in cerebral ammonia homeostasis, Neurochem Res, 37, 2355, 10.1007/s11064-012-0803-4 · DOI · Paper page
  91. Ito, 2001, Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain, Stroke, 32, 1208, 10.1161/01.STR.32.5.1208 · DOI · Paper page
  92. Kirschstein, 2012, Synaptic plasticity and learning in animal models of tuberous sclerosis complex, Neural Plast, 2012, 279834, 10.1155/2012/279834 · DOI
  93. Lee, 2015, Autism spectrum disorder and epilepsy: Disorders with a shared biology, Epilepsy Behav, 47, 191, 10.1016/j.yebeh.2015.03.017 · DOI · Paper page
  94. Switon, 2016, Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches, IUBMB Life, 68, 955, 10.1002/iub.1579 · DOI
  95. Switon, 2017, Molecular neurobiology of mTOR, Neuroscience, 341, 112, 10.1016/j.neuroscience.2016.11.017 · DOI · Paper page
  96. Goorden, 2007, Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures, Ann Neurol, 62, 648, 10.1002/ana.21317 · DOI · Paper page
  97. Ovsepian, 2017, Ambient Glutamate Promotes Paroxysmal Hyperactivity in Cortical Pyramidal Neurons at Amyloid Plaques via Presynaptic mGluR1 Receptors, Cereb Cortex, 27, 4733
  98. Ovsepian, 2016, Neuronal activity and amyloid plaque pathology: an update, J Alzheimers Dis, 49, 13, 10.3233/JAD-150544 · DOI · Paper page
  99. Ovsepian, 2019, Amyloid Plaques of Alzheimer's Disease as Hotspots of Glutamatergic Activity, Neuroscientist, 25, 288, 10.1177/1073858418791128 · DOI
  100. von der Brelie, 2006, Impaired synaptic plasticity in a rat model of tuberous sclerosis, Eur J Neurosci, 23, 686, 10.1111/j.1460-9568.2006.04594.x · DOI · Paper page
  101. Chu-Shore, C., et al., The natural history of epilepsy in tuberous sclerosis complex. , ed. Epilepsia. 2010, John Wiley & Sons, Ltd; 2010;51(7):1236–1241. · DOI · Paper page
  102. Vignoli, A., et al., Epilepsy in TSC: Certain etiology does not mean certain prognosis. Epilepsia. . 2013: John Wiley & Sons, Ltd. · DOI
  103. Kobayashi, 2001, A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice, Proc Natl Acad Sci U S A, 98, 8762, 10.1073/pnas.151033798 · DOI · Paper page
  104. Zeng, 2011, Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex, Hum Mol Genet, 20, 445, 10.1093/hmg/ddq491 · DOI · Paper page
  105. Onda, 1999, Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background, J Clin Invest, 104, 687, 10.1172/JCI7319 · DOI · Paper page
  106. Way, 2009, Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse, Hum Mol Genet, 18, 1252, 10.1093/hmg/ddp025 · DOI · Paper page
  107. Crowell, B., et al., Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123). eNeuro, 2015. 2(6):ENEURO.0046-15.2015. https://doi.org/10.1523/ENEURO.0046-15.2015. · DOI
  108. Steele, 1999, Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5, Hippocampus, 9, 118, 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8 · DOI · Paper page
  109. Waltereit, 2011, Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats, Behav Genet, 41, 364, 10.1007/s10519-010-9399-0 · DOI · Paper page

Cited by

See all 11

Metadata

Authors
Kútna, V., O'Leary, V. B., Newman, E., Hoschl, C., & Ovsepian, S. V.
Venue
Neurotherapeutics
Publisher
Elsevier BV
Published
2021-04
Volume
18
Issue
2
Pages
845-858
ISSN
1878-7479
Cited by
11
References
13
Language
en
Licence
Funders
NUP (LO1611)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes. https://app.cochat.ai/papers/10.1007/s13311-020-01000-7
The paper
Kútna, V., O'Leary, V. B., Newman, E., Hoschl, C., & Ovsepian, S. V. (2021). Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes. Neurotherapeutics. https://doi.org/10.1007/s13311-020-01000-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.